Image © Sun Pharma

On February 1, 2016, a generic version of imatinib myeselate (Gleevec®) was made available in the United States. Sun Pharmaceuticals (India) was first to file an ANDA (Abbreviated New Drug Application) with the US Food and Drug Administration (FDA) and has been granted marketing exclusivity for the first 180 days, after which other companies may begin marketing their generic versions as well.

To assist you as you consider which drug is most appropriate for your situation. The National CML Society has assembled this Generic Gleevec FAQ.

Press Release: Sun Pharma Imatinib Approval